107 related articles for article (PubMed ID: 9353408)
1. Control of lymphoproliferative and autoimmune disease in MRL-lpr/lpr mice by brequinar sodium: mechanisms of action.
Xu X; Gong H; Blinder L; Shen J; Williams JW; Chong AS
J Pharmacol Exp Ther; 1997 Nov; 283(2):869-75. PubMed ID: 9353408
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo mechanisms of action of the antiproliferative and immunosuppressive agent, brequinar sodium.
Xu X; Williams JW; Shen J; Gong H; Yin DP; Blinder L; Elder RT; Sankary H; Finnegan A; Chong AS
J Immunol; 1998 Jan; 160(2):846-53. PubMed ID: 9551920
[TBL] [Abstract][Full Text] [Related]
3. Suppression of autoimmune disease and of massive lymphadenopathy in MRL/Mp-lpr/lpr mice lacking tyrosine kinase Fyn (p59fyn).
Takahashi T; Yagi T; Kakinuma S; Kurokawa A; Okada T; Takatsu K; Aizawa S; Katagiri T
J Immunol; 1997 Sep; 159(5):2532-41. PubMed ID: 9278347
[TBL] [Abstract][Full Text] [Related]
4. The antilymphocytic activity of brequinar sodium and its potentiation by cytidine. Effects on lymphocyte proliferation and cytokine production.
Woo J; Lemster B; Tamura K; Starzl TE; Thomson AW
Transplantation; 1993 Aug; 56(2):374-81. PubMed ID: 8356593
[TBL] [Abstract][Full Text] [Related]
5. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice.
Xu X; Blinder L; Shen J; Gong H; Finnegan A; Williams JW; Chong AS
J Immunol; 1997 Jul; 159(1):167-74. PubMed ID: 9200452
[TBL] [Abstract][Full Text] [Related]
6. 5-Azacytidine inhibits the lpr gene-induced lymphadenopathy and acceleration of lupus-like syndrome in MRL/MpJ-lpr/lpr mice.
Yoshida H; Yoshida M; Merino R; Shibata T; Izui S
Eur J Immunol; 1990 Sep; 20(9):1989-93. PubMed ID: 1698637
[TBL] [Abstract][Full Text] [Related]
7. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.
Okazaki H; Hirata D; Kamimura T; Sato H; Iwamoto M; Yoshio T; Masuyama J; Fujimura A; Kobayashi E; Kano S; Minota S
J Rheumatol; 2002 Apr; 29(4):707-16. PubMed ID: 11950011
[TBL] [Abstract][Full Text] [Related]
8. Acceleration of lpr lymphoproliferative and autoimmune disease by transgenic protein kinase CK2 alpha.
Rifkin IR; Channavajhala PL; Kiefer HL; Carmack AJ; Landesman-Bollag E; Beaudette BC; Jersky B; Salant DJ; Ju ST; Marshak-Rothstein A; Seldin DC
J Immunol; 1998 Nov; 161(10):5164-70. PubMed ID: 9820486
[TBL] [Abstract][Full Text] [Related]
9. PI3K/AKT/mTOR hypersignaling in autoimmune lymphoproliferative disease engendered by the epistatic interplay of Sle1b and FASlpr.
Xie C; Patel R; Wu T; Zhu J; Henry T; Bhaskarabhatla M; Samudrala R; Tus K; Gong Y; Zhou H; Wakeland EK; Zhou XJ; Mohan C
Int Immunol; 2007 Apr; 19(4):509-22. PubMed ID: 17369192
[TBL] [Abstract][Full Text] [Related]
10. In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients.
Peters GJ; Schwartsmann G; Nadal JC; Laurensse EJ; van Groeningen CJ; van der Vijgh WJ; Pinedo HM
Cancer Res; 1990 Aug; 50(15):4644-9. PubMed ID: 2164443
[TBL] [Abstract][Full Text] [Related]
11. Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice.
Kulkarni O; Eulberg D; Selve N; Zöllner S; Allam R; Pawar RD; Pfeiffer S; Segerer S; Klussmann S; Anders HJ
J Pharmacol Exp Ther; 2009 Feb; 328(2):371-7. PubMed ID: 18997060
[TBL] [Abstract][Full Text] [Related]
12. Expression in transgenic mice of dominant interfering Fas mutations: a model for human autoimmune lymphoproliferative syndrome.
Choi Y; Ramnath VR; Eaton AS; Chen A; Simon-Stoos KL; Kleiner DE; Erikson J; Puck JM
Clin Immunol; 1999 Oct; 93(1):34-45. PubMed ID: 10497009
[TBL] [Abstract][Full Text] [Related]
13. Genetic determinants of autoimmune disease and coronary vasculitis in the MRL-lpr/lpr mouse model of systemic lupus erythematosus.
Gu L; Weinreb A; Wang XP; Zack DJ; Qiao JH; Weisbart R; Lusis AJ
J Immunol; 1998 Dec; 161(12):6999-7006. PubMed ID: 9862736
[TBL] [Abstract][Full Text] [Related]
14. Novel mechanisms of brequinar sodium immunosuppression on T cell activation.
Forrest TL; Ware RE; Howard T; Jaffee BD; Denning SM
Transplantation; 1994 Oct; 58(8):920-6. PubMed ID: 7940736
[TBL] [Abstract][Full Text] [Related]
15. Experimental treatment of autoimmune MRL-lpr/lpr mice with immunosuppressive compound FK506.
Yamamoto K; Mori A; Nakahama T; Ito M; Okudaira H; Miyamoto T
Immunology; 1990 Feb; 69(2):222-7. PubMed ID: 1689694
[TBL] [Abstract][Full Text] [Related]
16. Effect of cyclophosphamide on lymphokine production in MRL/lpr.Yaa mice.
Kamada H; Takaoka Y; Kitagaki K; Nagai H
Inflamm Res; 1995 Nov; 44(11):491-8. PubMed ID: 8597884
[TBL] [Abstract][Full Text] [Related]
17. Clear suppression of Th1 responses but marginal amelioration of autoimmune manifestations by IL-12p40 transgene in MRL-FAS(lprcg)/FAS(lprcg) mice.
Yasuda T; Yoshimoto T; Tsubura A; Matsuzawa A
Cell Immunol; 2001 Jun; 210(2):77-86. PubMed ID: 11520074
[TBL] [Abstract][Full Text] [Related]
18. Correlation of renal tubular epithelial cell-derived interleukin-18 up-regulation with disease activity in MRL-Faslpr mice with autoimmune lupus nephritis.
Faust J; Menke J; Kriegsmann J; Kelley VR; Mayet WJ; Galle PR; Schwarting A
Arthritis Rheum; 2002 Nov; 46(11):3083-95. PubMed ID: 12428253
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of action of the novel anticancer agent 6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarbo xylic acid sodium salt (NSC 368390): inhibition of de novo pyrimidine nucleotide biosynthesis.
Chen SF; Ruben RL; Dexter DL
Cancer Res; 1986 Oct; 46(10):5014-9. PubMed ID: 3019518
[TBL] [Abstract][Full Text] [Related]
20. Suppressive effect of a traditional Japanese medicine, Hachimi-jio-gan (Ba-Wei-Di-Huang-Wan), on the hyperresponsiveness to IL-18 in autoimmune MRL/MPJ-lpr/lpr mice.
Furuya Y; Kawakita T; Nomoto K
Int Immunopharmacol; 2003 Mar; 3(3):365-73. PubMed ID: 12639814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
